243 related articles for article (PubMed ID: 30482914)
1. Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.
Tian J; Raffa FA; Dai M; Moamer A; Khadang B; Hachim IY; Bakdounes K; Ali S; Jean-Claude B; Lebrun JJ
Br J Cancer; 2018 Dec; 119(12):1495-1507. PubMed ID: 30482914
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease.
Sato K; Padgaonkar AA; Baker SJ; Cosenza SC; Rechkoblit O; Subbaiah DRCV; Domingo-Domenech J; Bartkowski A; Port ER; Aggarwal AK; Ramana Reddy MV; Irie HY; Reddy EP
Nat Commun; 2021 Aug; 12(1):4671. PubMed ID: 34344863
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer.
Haga Y; Higashisaka K; Yang L; Sekine N; Lin Y; Tsujino H; Nagano K; Tsutsumi Y
Biochem Biophys Res Commun; 2020 Dec; 533(4):672-678. PubMed ID: 33036754
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapeutic Stress Influences Epithelial-Mesenchymal Transition and Stemness in Cancer Stem Cells of Triple-Negative Breast Cancer.
Li X; Strietz J; Bleilevens A; Stickeler E; Maurer J
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936348
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.
McKnight BN; Kim S; Boerner JL; Viola NT
Breast Cancer Res; 2020 Apr; 22(1):37. PubMed ID: 32295603
[TBL] [Abstract][Full Text] [Related]
6. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer.
Zhou L; Wang D; Sheng D; Xu J; Chen W; Qin Y; Du R; Yang X; He X; Xie N; Liu S; Zhang L
Theranostics; 2020; 10(5):2405-2421. PubMed ID: 32104513
[No Abstract] [Full Text] [Related]
7. FBXL2 promotes E47 protein instability to inhibit breast cancer stemness and paclitaxel resistance.
Li F; Niu M; Qin K; Guo R; Yi Y; Xu J; Li L; Xie S; Fu M; Wen N; Liao W; Xiao ZJ
Oncogene; 2023 Jan; 42(5):339-350. PubMed ID: 36460773
[TBL] [Abstract][Full Text] [Related]
8. Identification of a Triple Drug Combination That Is Synergistically Cytotoxic for Triple-Negative Breast Cancer Cells Using a Novel Combination Discovery Approach.
Ahmad S; He Q; Williams KP; Scott JE
SLAS Discov; 2020 Sep; 25(8):923-938. PubMed ID: 32441190
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer.
Corrales-Sánchez V; Noblejas-López MDM; Nieto-Jiménez C; Pérez-Peña J; Montero JC; Burgos M; Galán-Moya EM; Pandiella A; Ocaña A
J Cell Mol Med; 2020 Mar; 24(5):3117-3127. PubMed ID: 32032474
[TBL] [Abstract][Full Text] [Related]
10. LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling.
Luo F; Zhang M; Sun B; Xu C; Yang Y; Zhang Y; Li S; Chen G; Chen C; Li Y; Feng H
Mol Cancer; 2024 Mar; 23(1):60. PubMed ID: 38520019
[TBL] [Abstract][Full Text] [Related]
11. An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer.
Qayoom H; Wani NA; Alshehri B; Mir MA
Future Oncol; 2021 Nov; 17(31):4185-4206. PubMed ID: 34342489
[TBL] [Abstract][Full Text] [Related]
12. Targeting CD73 with flavonoids inhibits cancer stem cells and increases lymphocyte infiltration in a triple-negative breast cancer mouse model.
Mediratta K; El-Sahli S; Marotel M; Awan MZ; Kirkby M; Salkini A; Kurdieh R; Abdisalam S; Shrestha A; Di Censo C; Sulaiman A; McGarry S; Lavoie JR; Liu Z; Lee SH; Li X; Sciumè G; D'Costa VM; Ardolino M; Wang L
Front Immunol; 2024; 15():1366197. PubMed ID: 38601156
[TBL] [Abstract][Full Text] [Related]
13. Human Primary Breast Cancer Stem Cells Are Characterized by Epithelial-Mesenchymal Plasticity.
Strietz J; Stepputtis SS; Follo M; Bronsert P; Stickeler E; Maurer J
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670400
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness.
Lan J; Wei G; Liu J; Yang F; Sun R; Lu H
Theranostics; 2022; 12(6):2598-2612. PubMed ID: 35401817
[No Abstract] [Full Text] [Related]
15. Targeting the Id1-Kif11 Axis in Triple-Negative Breast Cancer Using Combination Therapy.
Thankamony AP; Murali R; Karthikeyan N; Varghese BA; Teo WS; McFarland A; Roden DL; Holliday H; Konrad CV; Cazet A; Dodson E; Yang J; Baker LA; George JT; Levine H; Jolly MK; Swarbrick A; Nair R
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32911668
[TBL] [Abstract][Full Text] [Related]
16. An in vitro study on the reversal of epithelial to mesenchymal transition by brusatol and its synergistic properties in triple-negative breast cancer cells.
Chandrasekaran J; Balasubramaniam J; Sellamuthu A; Ravi A
J Pharm Pharmacol; 2021 Apr; 73(6):749-757. PubMed ID: 33769483
[TBL] [Abstract][Full Text] [Related]
17. 1-Chromonyl-5-Imidazolylpentadienone Demonstrates Anti-Cancer Action against TNBC and Exhibits Synergism with Paclitaxel.
Modi K; Lawson S; Chen G; Tumuluri D; Rekhtman I; Kurtz M; Brailoiu GC; Chen QH; Lakshmikuttyamma A
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806551
[TBL] [Abstract][Full Text] [Related]
18. Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.
Lee S; Hu Y; Loo SK; Tan Y; Bhargava R; Lewis MT; Wang XS
Proc Natl Acad Sci U S A; 2020 May; 117(18):9912-9921. PubMed ID: 32321829
[TBL] [Abstract][Full Text] [Related]
19. HES1 promotes breast cancer stem cells by elevating Slug in triple-negative breast cancer.
Li X; Li Y; Du X; Wang X; Guan S; Cao Y; Jin F; Li F
Int J Biol Sci; 2021; 17(1):247-258. PubMed ID: 33390847
[TBL] [Abstract][Full Text] [Related]
20. Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling.
Zhang J; Xu HX; Wu YL; Cho WCS; Xian YF; Lin ZX
Adv Biol (Weinh); 2023 Aug; 7(8):e2300062. PubMed ID: 37401656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]